All In Biotech

Drug Trial Radar · NCT05682144

ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I

A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients With Mucopolysaccharidosis Type I Hurler-Scheie and Scheie

Last checked: Nov 20, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

11

Planned (sponsor's estimate)

Start

Apr 12, 2023

Primary completion

Jun 1, 2029

Study completion Jun 1, 2044

Sponsor

Lead sponsor
Immusoft of CA, Inc.Industry
Sponsor type
Industry
First posted
Jan 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A first-in-human study using ISP-001 in patients with Mucopolysaccharidosis Type I Hurler-Scheie and Scheie.

Conditions

  • Mucopolysaccharidosis IH/S
  • Mucopolysaccharidosis IS

Interventions

  • Autologous Plasmablasts (B cells)Biological

    Autologous plasmablasts (B cells) engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty (SB) transposon system.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events and serious adverse eventsTime frame: 24 Weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.